← All trials
NCT05870462
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 29, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- May 23, 2023
- Last posted
- Jul 25, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canadian Medical and Surgical Knowledge Translation Research GroupLead sponsor
- Unity Health TorontoCollaborator
- Unity Health TorontoOverall official - principal investigator
- Unity Health TorontoStudy chair
- University of Western OntarioCollaborator
- University of Western OntarioOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.